IN2014CN04530A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04530A
IN2014CN04530A IN4530CHN2014A IN2014CN04530A IN 2014CN04530 A IN2014CN04530 A IN 2014CN04530A IN 4530CHN2014 A IN4530CHN2014 A IN 4530CHN2014A IN 2014CN04530 A IN2014CN04530 A IN 2014CN04530A
Authority
IN
India
Prior art keywords
compounds
symbols
formula
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Smith
Francisco Xavier Talamas
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014CN04530A publication Critical patent/IN2014CN04530A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
IN4530CHN2014 2011-12-20 2012-12-17 IN2014CN04530A (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577712P 2011-12-20 2011-12-20
PCT/EP2012/075688 WO2013092447A1 (en) 2011-12-20 2012-12-17 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication

Publications (1)

Publication Number Publication Date
IN2014CN04530A true IN2014CN04530A (ro) 2015-09-11

Family

ID=47469968

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4530CHN2014 IN2014CN04530A (ro) 2011-12-20 2012-12-17

Country Status (31)

Country Link
US (1) US9708357B2 (ro)
EP (1) EP2794628B1 (ro)
JP (1) JP6118336B2 (ro)
KR (1) KR101687084B1 (ro)
CN (2) CN108409820A (ro)
AU (1) AU2012357986B2 (ro)
BR (1) BR112014015066A2 (ro)
CA (1) CA2869317C (ro)
CL (1) CL2014001599A1 (ro)
CO (1) CO6990719A2 (ro)
CR (1) CR20140255A (ro)
CY (1) CY1119015T1 (ro)
DK (1) DK2794628T3 (ro)
EA (1) EA024847B1 (ro)
ES (1) ES2626484T3 (ro)
HK (2) HK1199037A1 (ro)
HU (1) HUE033332T2 (ro)
IL (1) IL232843B (ro)
IN (1) IN2014CN04530A (ro)
LT (1) LT2794628T (ro)
MA (1) MA35749B1 (ro)
MX (1) MX350810B (ro)
PE (1) PE20141599A1 (ro)
PH (1) PH12014501283A1 (ro)
PL (1) PL2794628T3 (ro)
PT (1) PT2794628T (ro)
SG (1) SG11201403086YA (ro)
SI (1) SI2794628T1 (ro)
UA (1) UA110428C2 (ro)
WO (1) WO2013092447A1 (ro)
ZA (1) ZA201404444B (ro)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
BR112014015066A2 (pt) 2011-12-20 2017-06-13 Hoffmann La Roche derivados de nucleosídeos 4'azido-3'-flúor substituídos como inibidores de replicação do rna de hcv
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
JP6140815B2 (ja) 2012-05-25 2017-05-31 ヤンセン・サイエンシズ・アイルランド・ユーシー ウラシルスピロオキセタンヌクレオシド
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
BR112015028765A2 (pt) * 2013-05-16 2017-07-25 Riboscience Llc derivados de nucleosídeo substituído 4'-azido, 3'-desoxi-3'-fluoro
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2017040766A1 (en) * 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral tetrahydrofurane derivatives
WO2020007070A1 (zh) * 2018-07-02 2020-01-09 河南真实生物科技有限公司 4'-取代核苷的晶型、制备和应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (en) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Antibacterial compounds, use and preparation thereof
JPS6422823A (en) * 1987-07-17 1989-01-25 Asahi Glass Co Ltd Antiulcer agent
US5449664A (en) 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
CN1515248A (zh) 1996-04-23 2004-07-28 ��̩��˹ҩ��ɷ����޹�˾ 用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
PL192280B1 (pl) 1996-10-18 2006-09-29 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowania
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT966465E (pt) 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
IL134233A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
DE69925918T2 (de) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketosäure-derivate als hemmstoffe von polymerasen
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002523371A (ja) 1998-08-21 2002-07-30 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
EP1109580A4 (en) 1998-09-04 2004-05-26 Viropharma Inc METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
EP1115286A4 (en) 1998-09-25 2003-07-23 Viropharma Inc METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM
AP1498A (en) 1999-03-19 2005-11-21 Vertex Pharma Inhibitors of impdh enzyme.
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DK1401825T3 (da) 2001-06-11 2009-11-09 Virochem Pharma Inc Thiophenderivater som antivirale midler mod flavivirus-infektion
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
WO2003037894A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
US20070004669A1 (en) 2002-06-21 2007-01-04 Carroll Steven S Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
KR20060061930A (ko) 2003-04-25 2006-06-08 길리애드 사이언시즈, 인코포레이티드 항암성 포스포네이트 유사체
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
KR101159575B1 (ko) 2004-01-30 2012-07-06 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ―３ 세린 프로테아제 저해제
CA2590115A1 (en) 2004-12-10 2006-06-15 Emory University 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
CN101287472B (zh) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
WO2008085508A2 (en) 2007-01-05 2008-07-17 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
EP2166016A1 (en) * 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
SG172921A1 (en) * 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
CN102686599B (zh) * 2009-09-29 2016-10-05 杨森产品有限公司 核苷的氨基磷酸酯衍生物
ES2524398T3 (es) 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
PE20171640A1 (es) 2010-09-22 2017-11-09 Alios Biopharma Inc Analogos de nucleotidos sustituidos
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
BR112014015066A2 (pt) 2011-12-20 2017-06-13 Hoffmann La Roche derivados de nucleosídeos 4'azido-3'-flúor substituídos como inibidores de replicação do rna de hcv

Also Published As

Publication number Publication date
HK1199037A1 (en) 2015-06-19
EP2794628A1 (en) 2014-10-29
HK1200835A1 (en) 2015-08-14
CL2014001599A1 (es) 2014-11-03
EA201491180A1 (ru) 2014-11-28
CO6990719A2 (es) 2014-07-10
KR20140108303A (ko) 2014-09-05
US20140369959A1 (en) 2014-12-18
CA2869317C (en) 2016-05-17
DK2794628T3 (en) 2017-07-10
AU2012357986B2 (en) 2017-02-02
MA35749B1 (fr) 2014-12-01
LT2794628T (lt) 2017-07-10
CA2869317A1 (en) 2013-06-27
PL2794628T3 (pl) 2017-09-29
SG11201403086YA (en) 2014-07-30
MX2014007028A (es) 2014-09-16
NZ625844A (en) 2016-08-26
KR101687084B1 (ko) 2016-12-15
EA024847B1 (ru) 2016-10-31
IL232843A0 (en) 2014-07-31
US9708357B2 (en) 2017-07-18
EP2794628B1 (en) 2017-03-29
JP2015500851A (ja) 2015-01-08
ES2626484T3 (es) 2017-07-25
PH12014501283A1 (en) 2014-09-08
HUE033332T2 (en) 2017-11-28
ZA201404444B (en) 2015-08-26
PT2794628T (pt) 2017-07-05
AU2012357986A1 (en) 2014-06-19
MX350810B (es) 2017-09-20
CY1119015T1 (el) 2018-01-10
JP6118336B2 (ja) 2017-04-19
BR112014015066A2 (pt) 2017-06-13
SI2794628T1 (sl) 2017-07-31
CN104011060A (zh) 2014-08-27
IL232843B (en) 2018-02-28
WO2013092447A1 (en) 2013-06-27
PE20141599A1 (es) 2014-10-30
UA110428C2 (uk) 2015-12-25
CN108409820A (zh) 2018-08-17
CR20140255A (es) 2014-08-20

Similar Documents

Publication Publication Date Title
IN2014CN04530A (ro)
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12015500260A1 (en) Neprilysin inhibitors
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
MY165087A (en) Neprilysin inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY175854A (en) Novel quinolone derivatives
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MX342212B (es) Inhibidores de neprilisina.
IN2015DN01119A (ro)
NZ608116A (en) Triazine-oxadiazoles
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
AU2012213775A8 (en) 7-azaindole derivatives
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX362879B (es) Usos novedosos.
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
TN2013000089A1 (en) Triazine-oxadiazoles